Chemotherapy Induced Neutropenia (CIN) Market Size
Market Size in USD Bn
CAGR5.1%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 5.1% |
| Market Concentration | Medium |
| Major Players | Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Mylan N.V. and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Chemotherapy Induced Neutropenia (CIN) Market Analysis
The chemotherapy induced neutropenia (CIN) market is estimated to be valued at USD 14.88 Bn in 2025 and is expected to reach USD 21.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032. The growth of this market is primarily driven by the growing prevalence of cancer cases worldwide and increasing adoption of chemotherapy as an effective treatment modality.